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Abstract
Background
Anti-human leukocyte antigen donor-specific antibodies (anti-HLA DSAs) are recognized as
a major barrier to patients’ access to organ transplantation and the major cause of graft fail-
ure. The capacity of circulating anti-HLA DSAs to activate complement has been suggested
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as a potential biomarker for optimizing graft allocation and improving the rate of successful
transplantations.
Methods and findings
To address the clinical relevance of complement-activating anti-HLA DSAs across all solid
organ transplant patients, we performed a meta-analysis of their association with transplant
outcome through a systematic review, from inception to January 31, 2018. The primary out-
come was allograft loss, and the secondary outcome was allograft rejection. A comprehen-
sive search strategy was conducted through several databases (Medline, Embase,
Cochrane, and Scopus).
A total of 5,861 eligible citations were identified. A total of 37 studies were included in the
meta-analysis. Studies reported on 7,936 patients, including kidney (n = 5,991), liver (n =
1,459), heart (n = 370), and lung recipients (n = 116). Solid organ transplant recipients with
circulating complement-activating anti-HLA DSAs experienced an increased risk of allograft
loss (pooled HR 3.09; 95% CI 2.55–3.74, P = 0.001; I2 = 29.3%), and allograft rejection
(pooled HR 3.75; 95% CI: 2.05–6.87, P = 0.001; I2 = 69.8%) compared to patients without
complement-activating anti-HLA DSAs. The association between circulating complement-
activating anti-HLA DSAs and allograft failure was consistent across all subgroups and sen-
sitivity analyses. Limitations of the study are the observational and retrospective design of
almost all included studies, the higher proportion of kidney recipients compared to other
solid organ transplant recipients, and the inclusion of fewer studies investigating allograft
rejection.
Conclusions
In this study, we found that circulating complement-activating anti-HLA DSAs had a signifi-
cant deleterious impact on solid organ transplant survival and risk of rejection. The detection
of complement-activating anti-HLA DSAs may add value at an individual patient level for
noninvasive biomarker-guided risk stratification.
Trial registration
National Clinical Trial protocol ID: NCT03438058.
Author summary
Why was this study done?
• Allograft rejection is a major threat to allografts, with consequences for the patients in
terms of mortality and morbidity.
• Over the last decade, studies on solid organ transplant patients have reported that com-
plement-activating anti-human leukocyte antigen donor-specific antibodies (anti-HLA
DSAs) are highly associated with allograft rejection and failure, with varying magnitudes
of effect.
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What did the researchers do and find?
• This study was designed to evaluate the clinical relevance of complement-activating
anti-HLA DSAs at a population level and across the entire solid organ transplants spec-
trum (kidney, liver, heart, and lung transplant patients).
• The present meta-analysis, including 37 studies and 7,936 patients, provides evidence
that circulating complement-activating anti-HLA DSAs are a major determinant of
long-term allograft rejection and allograft failure.
What do these findings mean?
• These results suggest that circulating complement-activating anti-HLA DSAs are poten-
tial noninvasive biomarkers to stratify the risk for allograft failure and rejection.
• Further research will be needed to investigate the possibility that the detection of these
antibodies might have therapeutic significance and could provide opportunities for a
pathogenesis-driven approach to prevention and/or treatment of rejection for solid
organ transplant recipients.
Introduction
Organ transplantation is the treatment of choice for many patients with end-stage chronic dis-
ease, which is an increasing burden on industrialized and newly industrialized countries [1,2].
Despite substantial progress in the development of effective immunosuppressive regimens,
thousands of allografts fail every year worldwide due to rejection, with immediate conse-
quences in terms of mortality, morbidity, and billions in extra costs to healthcare systems
[3,4]. In the past decade, the role of circulating anti-human leukocyte antigen donor-specific
antibodies (anti-HLA DSAs) has been increasingly recognized as a major contributing factor
to allograft rejection [5] and long-term allograft failure [6–9] in kidney transplantation [10],
with the same important associations more recently appreciated in lung [11], heart [7–12],
liver [13], intestinal [14], and pancreas transplants [15].
However, not all antibodies are equal in terms of pathogenicity, and they exert a heteroge-
neous influence on organ allograft outcomes, ranging from acute forms of rejection leading to
immediate allograft dysfunction and early allograft loss to more indolent or subclinical forms
leading to progressive allograft deterioration.
The inconsistent effects of anti-HLA antibodies on allograft outcomes, which limit their
prognostic value, has recently led to attempts to refine their assessment on the basis of patho-
genic characteristics to determine which anti-HLA DSAs carry the highest risk for adverse
transplant outcomes. Among the notable characteristics of HLA antibodies, their capacity to
activate complement has been suggested as a potential factor directing their pathogenicity in
the rejection process [16]. Data support that circulating anti-HLA DSAs have the ability to
activate complement by their complement component 1q (C1q), C3d, and C4d complement
fraction-binding capacities or by their immunoglobulin G3 (IgG3) subclass component, which
are associated with an increased risk of antibody-mediated rejection (ABMR) and allograft
loss in solid organ transplant recipients [16–25]. However, prior studies have reported differ-
ent magnitudes of effect for these antibodies, ranging from strong effects to the absence of
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associations with allograft outcomes [18,19,26–30], limiting their implementation in clinical
practice. Greater precision in predicting allograft outcomes using a mechanistically informed,
noninvasive biomarker generalizable to diverse solid organ transplants has been identified as a
major goal by professional societies (e.g., the European Society of Organ Transplantation, the
American Society for Transplantation, and the American Society of Transplant Surgeons), agen-
cies (e.g., the European Medicine Agency and the Food and Drug Administration) [31], and
consortia [32]. These groups have pointed to the need for such biomarkers as vital both to opti-
mizing allocation policy and to better stratifying the risk of long-term allograft failure for indi-
vidual patients. This meta-analysis aims to evaluate the role of complement-activating anti-HLA
DSAs on graft survival and graft rejection across the entire spectrum of solid organ transplants.
Methods
This meta-analysis is reported in adherence with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) and the reporting Meta-Analyses of Observational
Studies in Epidemiology (MOOSE) [33,34].
Data sources and searches
A comprehensive search was designed and conducted by an experienced librarian with input
from the study investigators. The complete protocol of the research strategy was prespecified
and the analysis plan prospectively written (S1 Text). Controlled vocabulary supplemented with
keywords was used to search for complement-activating anti-HLA DSAs in human solid organ
transplantation in any language. The following databases were included: Ovid MEDLINE In-
Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane
Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Sco-
pus. The research was conducted from database inception to January 31, 2018. Complement-
activating anti-HLA DSAs were defined by their capacity to activate complement cascade at dif-
ferent levels—C1q [23], C3d [35], C4d [26], or presence of IgG3 subtype [36].
The following keywords were used for the research: “solid organ transplantation,” “kidney
transplantation,” “liver transplantation,” “lung transplantation,” “heart transplantation,” “intes-
tines transplantation,” “donor specific anti-HLA antibodies,” “solid-phase assay,” “comple-
ment-activating DSA,” “C1q,” “C3d,” “C4d,” “IgG3 subclass,” “outcome,” “graft loss,” “graft
survival,” “ABMR,” and “rejection.” For comprehensiveness, we also reviewed all references
listed in the full-text publications and reviews on the subject that were not identified by our
search criteria. An example of the research strategy in the Ovid database is described in S2 Text.
Study selection
Studies of any relevant design and in any language on the impact of complement-activating
anti-HLA DSAs on long-term graft survival and/or the risk of rejection were initially selected.
The eligible studies included all solid organ transplant patients (kidney, liver, lung, heart, and
intestinal transplantation), both adult or pediatric patients. Anti-HLA DSAs detected by the
Luminex single-antigen bead (SAB) technique were required for the DSA detection technique.
Complement-activating anti-HLA DSAs were defined according to their ability to bind C1q,
C3d, C4d or their IgG3 subclass. The endpoints of interest for inclusion were either allograft
loss for the primary endpoint and/or biopsy-proven rejection as a secondary endpoint. Allo-
graft rejection was labelled either antibody-mediated or mixed-rejection as defined by the
Banff international classification for kidney and liver transplants [37,38] or the International
Society for Heart and Lung Transplantation (ISHLT) classification for heart and lung trans-
plants [39]. Data on graft loss (hazard ratio [HR]) and/or allograft rejection (HR or odds ratio
Complement-activating anti-HLA antibodies and solid organ transplant survival: A meta-analysis
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[OR]) were extracted when available and defined as effect sizes with their 95% confidence
intervals (CIs).
The corresponding author of each eligible study was contacted and asked to provide HRs
and/or ORs when these were not available in the manuscript. All initial communications with
authors were based on a template explaining the study and the data required. Two separate
reminders were sent unless we received a definitive response. When no answer was obtained,
the study was excluded from the analysis.
We excluded unrelated articles, including those without information on complement-acti-
vating anti-HLA DSAs, duplicates, those with nonhuman results or non–solid-organ trans-
plant data, case reports, abstract-only articles, and reviews.
Two reviewers (C Loheac and A Bouquegneau) independently assessed the potential eligi-
bility of each of the titles and abstracts that resulted from the search and then reviewed the full
texts of all potentially eligible studies. Chance-adjusted inter-reviewer agreement (kappa statis-
tic) was calculated. All disagreements were resolved by consensus between reviewers and prin-
cipal investigators (C Lefaucheur and A Loupy).
Data extraction and quality assessment
The collected data included author name, year of publication, study size, mean or median follow-
up time, mean age of population, type of complement-activating anti-HLA DSA, comparison
used (patients with complement-activating anti-HLA DSAs were either compared to patients
without complement-activating anti-HLA DSAs, patients with non-complement activating anti-
HLA DSAs detected, or a mixed group of patients without anti-HLA DSAs and with non-comple-
ment activating anti-HLA DSAs), effect sizes (HR and/or OR) and their 95% CIs, potential con-
founding factors, and unadjusted and adjusted estimated risks of graft loss or graft rejection.
Adjusted HRs and ORs were used when available; otherwise, univariate effect sizes were used.
We used the Newcastle–Ottawa Scale (NOS) to assess the methodological quality (i.e., risk
of bias) of nonrandomized studies [40]. NOS score was calculated on the basis of the following
3 major components: the selection of the study groups and ascertainment of exposure (0 to 4
points), quality of the adjustment for confounding variables (0 to 2 points), and ascertainment
of outcomes (0 to 3 points). A high NOS score represents high methodological quality. The
only randomized controlled trial was assessed using the Cochrane Risk of Bias tool. Details
regarding the NOS scoring system are provided in S3 Text.
Data synthesis and analysis
Meta-analysis was performed using a random-effects model [41] because of the anticipated
heterogeneity across studies. In a random-effects meta-analysis model, the effect sizes from the
studies that actually were performed are assumed to represent a random sample from a partic-
ular distribution of these effect sizes and take into account both within-study variability
(expressed by the CI in each study’s effect sizes) and between-study variability (heterogeneity).
The index group for comparison was patients with complement-activating anti-HLA DSAs,
and they were either compared to patients with non–complement-activating anti-HLA DSAs,
patients without anti-HLA DSAs detected, or a mixed group of patients without anti-HLA
DSAs and with non-complement activating anti-HLA DSAs.
Statistical heterogeneity and publication bias
Statistical heterogeneity across the studies was tested with the I2 index [42]. The I2 index
describes the percentage of total variation across studies due to heterogeneity rather than
chance. A value of 0% indicates no observed heterogeneity; values exceeding 50% may elicit
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considerable caution and warrant further analysis through subgroup analyses [43]. A low P
value of the I2 test (below 0.05) provides evidence of heterogeneity of intervention effects (vari-
ation in effect estimates beyond chance). Publication bias was visually assessed using funnel
plots and statistically assessed by the Egger’s bias coefficient, which weighted the regression of
the intervention effect on its standard error (SE), with weights inversely proportional to the
variance of the intervention effect [44]. P< 0.05 (2-sided) was considered statistically signifi-
cant for the presence of a publication bias.
We investigated the extent to which statistical heterogeneity between results of multiple
studies can be related to one or more characteristics of the studies by using metaregression
[45]. Metaregression merges meta-analytic techniques with linear regression principles (pre-
dicting treatment effects using covariates). Metaregression could also explore possible causes
of heterogeneity and ascertain stability of results between subgroup analyses. In the present
study, we decided to adjust effect sizes on the following covariates if available: date of publica-
tion, mean fluorescence intensity (MFI) for anti-HLA DSAs, number of HLA mismatches,
period of inclusion, and mean recipient age. We used the overall model P value to assess
whether there is evidence for an association of any of the covariates with the outcome [46].
Subgroup and sensitivity analyses
These analyses were performed to explore potential sources of heterogeneity regarding the pri-
mary outcome and to assess the consistency of our results, and the choice of the different subgroup
analyses was prespecified prior to any analysis. The following subgroup analyses were considered.
Comparator group used. Considering the index group (complement-activating anti-
HLA DSA), we analyzed separately the studies comparing patients with non–complement-
activating anti-HLA DSAs or control consisting of a mixed group of patients with non–com-
plement-activating anti-HLA DSAs and without anti-HLA DSAs.
Studies that used multivariable models. Studies using multivariable models for address-
ing the independent associations of complement activation with allograft failure were analyzed
separately.
High versus low methodological quality studies. Articles with NOS scores6 (versus
lower scores) were selected as high-quality studies [47] and analyzed separately.
Type of organ transplanted. Kidney allograft versus all other types of transplanted organs
(heart, lung, and liver allografts). We decided to gather together the groups of liver, lung, and
heart transplantation because of their low number. Indeed, with a low number of studies (3 or
fewer), the risk of increasing the heterogeneity is important.
Timing of antibody detection. Preexisting anti-HLA DSAs (defined as antibodies present
before or at the time of transplantation), de novo anti-HLA DSAs (defined as antibodies pres-
ent only after transplantation), or a combined group of preexisting and de novo DSAs.
Type of assay used for characterizing the complement-activating capacity of antibod-
ies. Assays were characterized as anti-HLA DSA IgG subclass, C1q-binding anti-HLA DSAs,
C4d-binding anti-HLA DSAs, or C3d-binding anti-HLA DSAs. Because IgG subclass and
complement-binding tests may not provide the exact same information and biological proper-
ties, we performed a post hoc supplemental analysis on the impact of complement-binding
anti-HLA DSAs (C1q, C3d, and C4d) and the IgG3 subclass studies and their respective associ-
ations with allograft outcome.
Center effect. This subgroup analysis excluded the largest cohorts (in terms of the num-
ber of patients included) [16,48,49]. We performed this analysis because larger studies could
be a main driving factor for the associations found in primary analyses and could also modify
overall heterogeneity.
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Analyses were conducted using STATA (version 14.1; StataCorp, College Station, TX).
Results
Study identification and characteristics
The electronic search identified 5,861 potentially relevant citations. A schematic diagram of
the literature search procedure used in the present study is shown in Fig 1. The kappa statistic
for study eligibility was 0.9941 between the two reviewers (SE = 0.0949). Finally, 37 studies and
7,936 patients were included in the final meta-analysis, including 24 studies with data on
Fig 1. Flow chart summarizing the research strategy for study identification and selection. DSA, donor-specific antibody; SAB,
single-antigen bead.
https://doi.org/10.1371/journal.pmed.1002572.g001
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allograft loss, 8 studies with data on rejection, and 5 studies with both primary- and second-
ary-outcome data. Table 1 summarizes characteristics of the included studies. S1 Table pro-
vides a detailed characteristic of included studies.
Overall, 22 (59.5%) studies originated from Europe, 9 (24.3%) originated from North
America, 4 (10.8%) originated from the United Kingdom, and 2 (5.4%) originated from Asia.
The patients included were kidney recipients (n = 5,991; 75.5%), liver recipients (n = 1,459;
18.4%), heart recipients (n = 370; 4.7%), and lung recipients (n = 116; 1.4%). None of the stud-
ies included patients with intestine or pancreas transplantation. Complement-activating anti-
HLA DSAs were assessed by their capacity to bind C1q (19 studies), C4d (6 studies), or C3d (4
studies) or by their IgG subclass composition (8 studies). Six studies simultaneously analyzed 2
complement-activating anti-HLA DSA assays [17,20,24,48,49,56]. The mean patient follow-up
time post transplantation was 71.2 ± 32.3 months. None of the studies included were spon-
sored or conducted by diagnostic companies involved in the manufacture or sale of comple-
ment-activating antibody assays. Nineteen authors were contacted and asked for
supplementary data, and 63% of them provided with the requested information.
The funnel plot presented in Fig 2 demonstrates the absence of a publication bias (Egger’s
test P = 0.224). The randomized controlled trial was of moderate quality [70]. The NOS scores
for quality assessments of the included studies are presented in S2 Table. The median NOS
score was 6 (minimum 3, maximum 9), with 2.8%, 2.8%, 19.4%, 38.9%, 22.2%, 11.1%, and
2.8% of studies having a NOS score of 3, 4, 5, 6, 7, 8, and 9, respectively.
Complement-activating anti-HLA DSA status and outcomes
Risk of allograft loss according to complement-activating anti-HLA DSA status.
Patients with complement-activating anti-HLA DSAs had a 3.09-fold increased risk of long-
term allograft loss compared to patients without anti-HLA DSAs, patients with non–comple-
ment-activating anti-HLA DSAs, and a mixed group including patients without anti-HLA
DSAs and with non–complement-activating anti-HLA DSAs (HR 3.09; 95% CI 2.55–3.74,
P = 0.001; I2 = 29.3%) (Fig 3).
Risk of allograft rejection according to complement-activating anti-HLA status.
Patients with complement-activating anti-HLA DSAs had a 3.75-fold increased risk of allograft
rejection compared to patients without anti-HLA DSAs, patients with non–complement-acti-
vating anti-HLA DSAs, and a mixed group including patients without anti-HLA DSAs and
with non–complement-activating anti-HLA DSAs (HR 3.75; 95% CI 2.05–6.87, P = 0.001; I2 =
69.8%) (Fig 4).
Subgroup and sensitivity analyses
Subgroup and sensitivity analyses were performed on the outcome of graft loss to confirm the
consistency of the results and explain some of the heterogeneity found in the overall results.
Table 2 summarizes the different effect sizes for the different subgroup analyses.
Effect of the complement-activating anti-HLA DSAs in studies with different compara-
tors used. Sensitivity analysis restricted to studies with different comparators used demon-
strated consistent results regarding the association between complement-activating anti-HLA
DSAs and risk of allograft loss, with a pooled HR of 2.94 for patients with complement-activat-
ing anti-HLA DSAs compared to patients with non–complement-activating anti-HLA DSAs
(95% CI 2.04–4.23, P = 0.001; I2 = 41.1%) (S1 Fig). The pooled HR for patients with comple-
ment-activating anti-HLA DSAs compared to patients with a mixed group of patients without
DSAs and with non–complement-activating DSAs was 3.60 (95% CI 2.74–4.73, P = 0.001; I2 =
0.0%) (S2 Fig).
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Table 1. Characteristics of the 37 included studies.
First author (date of
publication)
Population Study
type
Period of
inclusion
Number of
patients
Effect size (95% CI)
Wahrmann et al. (2009)
[26]
Retrospective, single-center analysis of consecutive adult renal
transplants selected based on the presence of pretransplant DSAs
Cohort 2001–2002 338 2.40 (0.90–6.00) for graft loss
10.10 (3.20–31.00) for
rejection
Ho¨nger et al. (2010) [28] Retrospective, single-center analysis of consecutive adult renal
transplant recipients with low levels of pretransplant DSAs
Cohort 1999–2004 64 0.93 (0.25–3.44) for rejection
Sutherland et al. (2011)
[50]
Retrospective, single-center analysis of pediatric renal transplant
recipients without DSAs at the time of transplantation
Cohort 2000–2008 35 5.80 (1.40–22.90) for graft
loss
Ho¨nger et al. (2011) [51] Retrospective, single-center analysis of adult renal transplant
recipients with high levels of DSAs pre transplant; recipients who
developed ABMR within 6 months
Cohort 1999–2008 71 0.43 (0.17–1.12) for rejection
Smith et al. (2011) [7] Retrospective, single-center analysis of living heart transplant
recipients after 1 year of transplantation without DSAs pre
transplant
Cohort 1995–2004 243 3.02 (1.11–8.23) for graft loss
Kaneku et al. (2012) [52] Retrospective (2-center) analysis of adult liver transplant
recipients with liver biopsies showing chronic rejection and DSA
analysis at the same time
Case-
control
NC 39 3.35 (1.39–8.05) for graft loss
Bartel et al. (2013) [53] Retrospective, single-center analysis of 68 desensitized renal
recipients who had been subjected to peritransplant
desensitization
Cohort 1999–2008 68 10.10 (1.60–64.20) for
rejection
Lawrence et al. (2013)
[54]
Retrospective, single-center study of consecutive renal transplant
recipients
Cohort 2005–2010 52 8.90 (1.20–65.86) for
rejection
Crespo et al. (2013) [55] Retrospective (2-center) analysis of renal transplant patients with
pretransplant DSAs
Cohort 2006–2011 355 0.83 (0.17–4.14) for graft loss
1.44 (0.23–9.11) for rejection
Loupy et al. (2013) [16] Consecutive adult patients in a retrospective (2-center) analysis;
unselected global population with DSA detection before or after
renal transplantation
Cohort 2004–2010 1,016 4.78 (2.69–8.49) for graft loss
Freitas et al. (2013) [56] Retrospective, single-center analysis of renal transplant recipients
selected on the basis of DSA detection during follow-up
Cohort 1999–2012 203 3.50 (1.30–9.50) for graft loss
Arnold et al. (2014) [57] Retrospective, single-center analysis of renal transplant recipients
without DSAs pre transplant and screened for de novo DSAs
Cohort 1997–2007 274 4.81 (1.65–14.03) for graft
loss
Smith et al. (2014) [25] Retrospective, single-center analysis of lung transplant recipients
with pretransplant DSA detection
Cohort 1991–2003 63 6.43 (2.96–13.97) for graft
loss
Everly et al. (2014) [58] Retrospective, single-center analysis of primary renal transplant
recipients without pretransplant DSA detection
Cohort 1999–2006 179 2.48 (1.02–6.04) for graft loss
O’Leary et al. (2015) [24] Retrospective, single-center analysis of consecutive patients with
1-year survival post liver transplantation;
one group analyzed pretransplant DSA effects, and another group
analyzed the impact of de novo DSAs
Cohort 2000–2009 1,270 1.90 (1.62–3.45) for C1q for
graft loss
2.40 (1.82–5.75) for IgG3 for
graft loss
Wozniak et al. (2015) [59] Retrospective, single-center analysis of pediatric liver transplant
patients who were either nontolerant, tolerant, or stable
Cohort NC 50 4.30 (1.10–16.40) for
rejection
Khovanova et al. (2015)
[60]
Retrospective, single-center analysis of HLA-incompatible
desensitized renal transplant patients
Cohort 2003–2012 80 1.69 (0.41–6.93) for
preexisting DSAs for graft
loss
2.09 (0.30–14.60) for
preexisting and de novo
DSAs for graft loss
Sicard et al. (2015) [17] Retrospective analysis of consecutive (2-center) adult renal
transplant patients who developed ABMR
Cohort 2004–2012 69 2.80 (1.12–6.95) for C3d for
graft loss
1.98 (0.95–4.14) for C1q for
graft loss
Thammanichanond et al.
(2016) [61]
Retrospective, single-center cohort study of patients with pre–
renal transplant DSAs
Cohort 2009–2013 48 2.20 (0.61–7.85) for rejection
(Continued)
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Table 1. (Continued)
First author (date of
publication)
Population Study
type
Period of
inclusion
Number of
patients
Effect size (95% CI)
Comoli et al. (2016) [20] Retrospective analysis of consecutive pediatric recipients; single
center; first kidney transplant without any HLA antibodies in sera
or at the time of transplantation
Cohort 2002–2013 114 6.91 (2.78–17.18) for
rejection and C3d
13.54 (4.95–36.99) for
rejection and C1q
27.80 (5.61–137.72) for graft
loss and C3d
11.09 (2.25–54.64) for graft
loss and C1q
Yamamoto et al. (2016)
[62]
Retrospective analysis of renal transplant patients with de novo
DSAs and surveillance biopsies
Cohort 2009–2013 43 2.60 (0.12–53.90) for
rejection
Calp–Inal et al. (2016)
[18]
Retrospective analysis; single center; consecutive renal transplant
patients: Group 1 without pretransplant DSAs and
Group 2 with a mix of preexisting and de novo DSAs
Cohort 2009–2012 284 4.30 (1.10–16.50) for graft
loss
Malheiro et al. (2016)
[63]
Retrospective, single-center analysis of kidney transplant patients
with DSAs pre transplant
Cohort 2007–2012 60 16.80 (3.18–88.85) for
rejection
Visentin et al. (2016) [64] Retrospective, single-center analysis of lung transplant patients
with biopsy (with demonstration of rejection) and serum
available
Cohort 1999–2014 53 1.65 (0.68–3.97) for graft loss
Kauke et al. (2016) [30] Retrospective, single-center analysis of patients selected based on
renal biopsy-proven rejection during graft dysfunction or viremia
with polyomavirus BK
Cohort 2005–2011 611 3.77 (1.40–10.16) for graft
loss
4.52 (1.89–10.37) for
rejection
Bamoulid et al. (2016)
[65]
Retrospective, single-center analysis of renal transplant
consecutive patients without DSAs pre transplant
Cohort 2007–2014 59 2.27 (1.05–4.91) for rejection
6.78 (0.86–53.50) for graft
loss
Fichtner et al. (2016) [21] Retrospective, single-center analysis of prospectively screened
renal transplant pediatric patients, non-presensitized
Cohort 1999–2010 62 6.35 (1.33–30.40) for graft
loss
Guidicelli et al. (2016)
[19]
Retrospective, single-center analysis of consecutive nonsensitized
kidney transplant patients
Cohort 1998–2005 346 2.99 (0.94–10.27) for graft
loss
Lefaucheur et al. (2016)
[48]
Retrospective analysis of consecutive patients (2-center); renal
transplant patients were unselected
Cohort 2008–2010 125 4.80 (1.70–13.30) for IgG3
for graft loss
3.60 (1.10–11.70) for C1q for
graft loss
Viglietti et al. (2017) [49] Retrospective analysis of consecutive patients (2-center); renal
transplant recipients were unselected
Cohort 2008–2011 851 4.25 (1.88–9.61) for IgG3 for
graft loss
3.60 (1.71–7.59) for C1q for
graft loss
Wiebe et al. (2017) [27] Retrospective analysis of consecutive adult and pediatric renal
transplant patients, single center; patients without pretransplant
sensitization
Cohort 1999–2012 70 1.06 (0.50–2.40) for graft loss
Moktefi et al. (2017) [66] Retrospective analysis (2-center) of patients selected based on the
development of acute renal ABMR and the presence of DSAs
Cohort 2005–2012 48 0.79 (0.25–2.44) for graft loss
Sicard et al. (2017) [67] Retrospective analysis of consecutive adult renal transplant
patients (2-center) with unselected patients
Cohort 2004–2012 52 3.71 (1.27–10.80) for graft
loss
Das et al. (2017) [68] Retrospective, single-center analysis of pediatric heart transplant
without DSAs pre transplantation and at the time of
transplantation
Cohort 2005–2014 127 3.20 (1.34–7.86) for graft loss
Couchonnal et al. (2017)
[69]
Retrospective analysis; single-center analysis of consecutive
pediatric liver transplant selected on the presence of DSAs during
follow-up
Cohort 1990–2014 100 4.12 (0.95–17.89) for graft
loss
Bailly et al. (2017) [70] Retrospective analysis of multicenter, prospective, randomized,
double-blind, placebo-controlled, parallel-group trials; patients
selected on the basis of renal ABMR development and DSA
detection; patients treated either with standard of care (PP plus
IVIg) or rituximab plus standard of care
Cohort 2008–2011 25 3.70 (0.80–17.00) for graft
loss
(Continued)
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Regarding the risk of rejection, the pooled HR for patients with complement-activating
anti-HLA DSAs compared to patients with non–complement-activating anti-HLA DSAs was
4.24 (95% CI 2.23–8.06, P = 0.001; I2 = 55.0%) (S3 Fig).
Multivariable models: Independent prognostic value of complement-activating anti-
HLA DSA. When selecting studies that performed multivariable models, adjusting comple-
ment-activating anti-HLA DSA status on pan-IgG anti-HLA DSA level defined by the MFI,
the presence of complement-activating anti-HLA DSAs remained significantly and indepen-
dently associated with an increased risk of allograft loss (HR 3.01; 95% CI 2.26–4.0, P = 0.001),
and the heterogeneity across studies decreased from 29.3% to 17.4% (Fig 5).
Effect of complement-activating anti-HLA DSAs in studies with high methodological
quality. Sensitivity analysis restricted to studies with high methodological quality (NOS
score6) demonstrated consistent results regarding the association between complement-
activating anti-HLA DSAs and the risk of long-term allograft loss, with a pooled HR of 2.87
Table 1. (Continued)
First author (date of
publication)
Population Study
type
Period of
inclusion
Number of
patients
Effect size (95% CI)
Molina et al. (2017) [71] Retrospective analysis; single-center analysis of consecutive adult
kidney transplant patients selected on pretransplant DSA
detection
Cohort 1995–2009 389 4.01 (2.33–6.92) for graft loss
Effect sizes refer to HR for graft survival and OR for rejection appearance.
Abbreviations: ABMR, antibody-mediated rejection; C1q, complement component 1q; CI, confidence interval; DSA, donor-specific antibody; HLA, human leukocyte
antigen; HR, hazard ratio; IgG3, immunoglobulin G3; IVIg: intravenous immunoglobulin; NC, not communicated; OR, odds ratio; PP, plasmapheresis.
https://doi.org/10.1371/journal.pmed.1002572.t001
Fig 2. Funnel plot representing the analysis for publication bias with Egger’s test for bias. Each dot represents a
study; the y-axis represents study precision (95% CIs), and the x-axis shows the SE of the HR. CI, confidence interval;
HR, hazard ratio; SE: standard error.
https://doi.org/10.1371/journal.pmed.1002572.g002
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(95% CI 2.42–3.39, P = 0.001; I2 = 3.1%) (S4 Fig). Sensitivity analysis restricted to studies with
lower methodological quality (NOS score5) demonstrated that complement-activating anti-
HLA DSAs were associated with the risk of long-term allograft loss, with a pooled HR of 3.82
(95% CI 1.75–8.33, P = 0.001; I2 = 67.8%).
Effect of complement-activating anti-HLA DSAs according to the type of solid organ
transplant. Sensitivity analysis restricted to kidney allograft recipients demonstrated an
increased risk of allograft loss associated with the presence of complement-activating anti-
HLA DSAs, with a pooled HR of 3.26 (95% CI 2.58–4.11, P = 0.001; I2 = 26.6%) (S5 Fig). The
analysis including heart, lung, and liver recipients showed a pooled HR of 2.71 (95% CI 1.98–
3.72, P = 0.001; I2 = 29.3%) (S5 Fig).
Fig 3. Association between circulating complement-activating anti-HLA DSAs and the risk of allograft loss. Fig 3 shows the forest plot of the association between
complement-activating anti-HLA DSAs and the risk of allograft loss for each study and overall (n = 29). Studies are listed by date of publication. Number of patients are
listed in the 3 cohort columns. The black diamond-shaped boxes represent the HR for each individual study. The grey boxes around the black diamond represent the
weight of the study, and lines represent the 95% CI for individual studies. The blue diamond at the end represents the pooled HR. The number of patients in the overall
population does not correspond to the sum of the different groups for the studies of Kaneku et al. (2012) (3 patients), Sicard et al. (2015) (4 patients), and Moktefi et al.
(2017) (3 patients) either because the data for these patients were missing or because they were not involved in the analysis. CI, confidence interval; DSA, donor-specific
antibody; HLA, human leukocyte antigen; HR, hazard ratio.
https://doi.org/10.1371/journal.pmed.1002572.g003
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Effect of complement-activating anti-HLA DSAs according to the timing of antibody
detection. We performed a stratified analysis according to the time of antibody detection.
We confirmed that in patients with either preexisting (HR 2.67; 95% CI 1.79–4.00, P = 0.001;
I2 = 52.7%) anti-HLA DSAs or de novo (HR 3.65; 95% CI 2.45–5.44, P = 0.001; I2 = 38.0%)
anti-HLA DSAs, complement-activating anti-HLA DSAs remained significantly associated
with an increased risk of allograft loss (S6 Fig).
Analysis according to the type of test used for detecting complement-activating anti-
bodies. Primary analyses were stratified according to the type of test used for detecting com-
plement-activating antibodies. We found consistent associations across the different methods
to detect complement-activating anti-HLA antibodies: (i) C1q-binding capacity (HR 2.80, 95%
CI 2.11–3.71, I2 = 42.1%), (ii) IgG3 subclass (HR 3.11, 95% CI 2.29–4.22, I2 = 0.0%), (iii) C3d-
binding capacity (HR 5.04, 95% CI 2.10–12.07, I2 = 51.2%), and (iv) C4d-binding capacity
(HR 3.82, 95% CI 2.05–7.11, I2 = 29.8%). Because IgG3 subclass DSA may not provide the
exact same information as complement-binding tests (C1q, C3d, C4d), we performed addi-
tional post hoc analyses and found similar associations when stratified according to comple-
ment-activating anti-HLA DSAs (C1q-, C3d-, and C4d-binding ability) and IgG subclass, with
a pooled HR of 3.11 (95% CI 2.42–4.0, P = 0.001) and 3.11 (95% CI 2.29–4.22, P = 0.001),
respectively (S7 Fig).
Fig 4. Association between complement-activating anti-HLA DSAs and the risk of rejection. Fig 4 shows the forest plot of the association between complement-
activating anti-HLA DSAs and the risk of rejection for each study and overall (n = 13). Studies are listed by date of publication. The black diamond-shaped boxes
represent the HR for each individual study. The grey boxes around the black diamond represent the weight of the study, and lines represent the 95% CI for individual
studies. The blue diamond at the end represents the overall HR. CI, confidence interval; DSA, donor-specific antibody; HLA, human leukocyte antigen; HR, hazard
ratio.
https://doi.org/10.1371/journal.pmed.1002572.g004
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Center effect. After removing the 3 largest studies from the analysis [16,48,49], the pres-
ence of complement-activating anti-HLA DSAs remained significantly associated with an
increased risk of allograft loss (HR 2.90; 95% CI 2.33–3.60, P = 0.001), and the heterogeneity
across studies remained stable at 31.8% (S8 Fig).
In order to identify additional factors explaining residual heterogeneity, we performed
metaregression and did not find any significant association between date of publication
(P = 0.664), mean MFI for anti-HLA DSA (P = 0.632), number of HLA mismatch (P = 0.582),
period of inclusion (P = 0.109), mean population age (P = 0.078), and the risk of allograft loss.
Discussion
In the present meta-analysis including 7,936 solid organ transplant patients, we established
that complement-activating anti-HLA DSAs represent an important determinant of allograft
loss across multiple types of organ transplants without a significant publication bias and with
acceptable heterogeneity. Patients with complement-activating anti-HLA DSAs have a 3-fold–
increased risk of allograft loss compared with patients without anti-HLA DSAs and/or patients
Table 2. Effect sizes related to the different subgroup analyses.
Subgroup analyses for allograft survival Effect
size
95% CI I2
P value
Effect of complement-activating anti-HLA DSAs in studies with
high or low methodological quality
High–methodological quality studies
NOS 6
2.87 2.42–
3.39
3.1%
P = 0.418
Low–methodological quality studies
NOS < 6
3.82 1.75–
8.33
67.8%
P = 0.005
Effect of complement-activating anti-HLA DSAs in studies with
different comparators used
Studies comparing index group and patients with non–
complement-activating anti-HLA DSAs
2.94 2.04–
4.23
41.1%
P = 0.036
Studies comparing index group and patients with non–
complement-activating anti-HLA DSAs and without anti-HLA
DSAs
3.60 2.74–
4.73
0.0%
P = 0.462
Effect of complement-activating anti-HLA DSAs according to the
type of solid organ transplant
Kidney transplantation studies only 3.26 2.58–
4.11
26.6%
P = 0.102
Heart, lung, and liver transplantation studies 2.71 1.98–
3.72
29.3%
P = 0.194
Effect of complement-activating anti-HLA DSAs according to the
timing of antibody detection
Preexisting DSAs 2.67 1.79–
4.00
52.7%
P = 0.048
Preexisting and de novo DSAs 3.18 2.49–
4.05
0.0%
P = 0.458
De novo DSAs 3.65 2.45–
5.44
38.0%
P = 0.081
Effect of complement-activating anti-HLA DSAs according to the
type of test used for detecting complement-activating antibodies
C1q 2.80 2.11–
3.71
42.1%
P = 0.028
C4d 3.82 2.05–
7.11
29.8%
P = 0.240
C3d 5.04 2.10–
12.07
51.2%
P = 0.105
IgG3 3.11 2.29–
4.22
0.0%
P = 0.868
Center effect 2.90 2.33–
3.60
31.8%
P = 0.050
Table 2 summarizes the effect sizes observed in the different subgroup analyses described in the Materials and methods. Effect sizes refer to HR for graft survival and OR
for rejection appearance. Index group refers to patients with complement-activating anti-HLA DSAs.
Abbreviations: C1q, complement component 1q; CI, confidence interval; DSA, donor-specific antibody; HLA, human leukocyte antigen; HR, hazard ratio; I2,
heterogeneity; IgG3, immunoglobulin G3; NOS, Newcastle–Ottawa scale; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1002572.t002
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with non–complement-activating anti-HLA DSAs. These associations were consistent regard-
ing long-term allograft loss in high-quality studies, across different solid organ transplant pop-
ulations (kidney, heart, lung, and liver transplant recipients), across different types of tests
used for detecting complement-activating anti-HLA DSAs, and at different times of evaluation
for complement-activating anti-HLA DSA status (before and after transplantation). Moreover,
beyond the effect on allograft survival, we found that complement-activating anti-HLA DSAs
were also strongly associated with an increased risk of allograft rejection. These findings rein-
force the robustness of the results and their applicability in different clinical scenarios and
transplant programs with different practices and support the possibility of a causal effect
between complement-activating antibodies and allograft injury.
One of the major hurdles in the quest to develop personalized medicine in transplantation
and improve overall transplant patient outcomes is the lack of valid, mechanistically-informed
noninvasive biomarkers for predicting allograft outcomes that can be used for patient risk
stratification, clinical trial design, and as surrogate endpoints. The recognition of the dominant
role of anti-HLA antibodies in rejection and late failure of kidney [10], heart [12], liver [13],
lung [11], or intestinal [14] transplants has been a turning point for transplant medicine in
the past decade. However, not all anti-HLA DSAs are equal in terms of pathogenicity and
Fig 5. Association of circulating complement-activating anti-HLA DSAs with the risk of allograft loss in selected studies with multivariable models including MFI
and complement-activating anti-HLA DSA. Fig 5 shows the forest plot of the association between complement-activating anti-HLA DSAs and the risk of allograft loss
in studies with multivariable models including MFI and complement-activating anti-HLA DSA (n = 8). Studies are listed by date of publication. The black diamond-
shaped boxes represent the HR for each individual study. The grey boxes around the black diamond represent the weight of the study, and lines represent the 95% CI for
individual studies. The blue diamond at the end represents the overall HR. The number of patients in the overall population does not correspond to the sum in the
different groups for the studies of Kaneku et al. (2012) (3 patients) and Sicard et al. (2015) (4 patients) either because the data for these patients were missing or because
they were not involved in the analysis. CI, confidence interval; DSA, donor-specific antibody; HLA, human leukocyte antigen; HR, hazard ratio; MFI, mean fluorescence
intensity.
https://doi.org/10.1371/journal.pmed.1002572.g005
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therefore may not be consistently associated with adverse allograft outcomes. Because activa-
tion of the complement cascade is an important component of the ABMR process, new
approaches have been developed to better characterize anti-HLA DSAs and link their capacity
to activate complement to the pathophysiology of transplant rejection. The complement-acti-
vating ability of anti-HLA antibodies and/or complement-activating IgG subclasses have been
shown to be associated with more severe rejection episodes and diminished long-term graft
survival [17,49,50]. However, some groups have reported different results, with varying magni-
tudes of effects ranging from strong to marginal associations between complement-activating
anti-HLA DSAs and allograft loss [19,27].
The results of this meta-analysis were robust across diverse subgroup analyses. First,
although kidney transplant patients represented the highest number of patients included in
the present meta-analysis, the effects of complement-activating anti-HLA DSAs on allograft
loss remained significant in heart, lung, and liver transplant patients. Grouping non-kidney
transplant studies together (liver, lung, and heart transplantation) as opposed to kidney trans-
plant studies was based on the larger volume of studies focusing on kidney transplant patients.
This mirrors the distribution of solid organ transplants worldwide (84,347 kidney transplanta-
tions among the 126,670 total organs transplanted) [72].
Second, the same effect was observed regardless of whether the antibody was preexisting or
de novo. Third, we found similar associations regardless of the type of test used for assessing
complement-activating anti-HLA DSAs.
In most of the studies included in this meta-analysis, a correlation existed between comple-
ment-activating antibody status and anti-HLA DSA level (assessed by MFI). Despite this corre-
lation, 8 studies included in the present meta-analysis with sufficient statistical power to
perform multivariable models demonstrated that the association between C1q-, C3d-binding
tests or IgG3 test and allograft outcomes was independent of the level of anti-HLA DSA MFI
(Fig 5). Moreover, the SAB assays can be falsely low, while the C1q assay is more accurate.
Therefore, the SAB assay has limitations that mislead the interpretation in comparing MFI ver-
sus C1q, C3d, or C4d assays [73]. In contrast to MFI that was reported in most of the studies
in this meta-analysis, anti-HLA DSA level determined by titer of antibody correlated with
complement-fixing ability [22,74]. In addition to the requirement of minimum titer of DSAs
(>1:16) to be complement fixing, the composition of IgG subtypes may also influence the
complement-binding capacity [48,75]. Therefore, C1q, C3d and IgG3 assays provide addi-
tional insights beyond the DSA strength/titer. Finally, the cutoffs used for antibody detection
and for complement-activating anti-HLA DSAs in the different studies was variable. These dif-
ferent cutoffs and technical issues in anti-HLA DSA detection, such as avoidance of the pro-
zone effect, are beyond the scope of the present study.
The heterogeneity (I2) found in the present study may be explained by (i) different tests and
protocols used for screening complement-activating antibodies (C1q, C4d, C3d, and IgG sub-
class), (ii) different types of transplant cohorts and clinical management, including risk-taking
strategies (high versus low immunological risk transplant populations), (iii) the timing of anti-
body detection before and after transplantation, and (iv) nonoptimal statistical power and sta-
tistical methodologies used in some studies. Despite this overall heterogeneity, when subgroup
analyses were performed including studies with high methodological quality, the heterogeneity
decreased from 29.3% to 3.1%. When patients with kidney transplantation were analyzed, the
heterogeneity remained stable. Also, when studies using multivariable models were selected in
the main analysis, the heterogeneity dropped to 17.4%. Last, despite the overall heterogeneity,
the association between complement-activating antibodies and allograft loss remained highly
significant in many different clinical scenarios, transplant populations, and relative to the tim-
ing of antibody detection, thereby reinforcing the study conclusions.
Complement-activating anti-HLA antibodies and solid organ transplant survival: A meta-analysis
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002572 May 25, 2018 16 / 25
The findings of the present study have important clinical implications. The magnitude of
the overall association found in the present study further reinforces the possibility of using cir-
culating complement-activating anti-HLA DSAs as a potential prognostic factor for allograft
loss in transplant patients. Relative to studies from other medical fields such as oncology or
cardiology, well-recognized prognostic biomarkers did not always provide associations as high
as the one observed in the present medical scenario [76–79]. Beyond their prognostic ability,
the characterization of complement-activating anti-HLA DSA properties may influence the
allocation system. The consolidation of the SAB–pan-IgG assay in the detection of preformed
anti-HLA antibodies has improved transplantation success. However, its high sensitivity has
limited the allograft allocation for sensitized patients. The result from this meta-analysis
reveals that not all anti-HLA DSAs detected by SAB–pan-IgG assays are equally pathogenic,
supporting that, overall, the neat-serum MFI value alone—which only offers a semiquantita-
tive measurement of antibody level—is not entirely reliable for predicting transplant outcome.
While the clinical use of SAB–C1q assay for the identification of unacceptable mismatches
would improve wait-listed patient stratification regarding their risk of allograft loss, it might
also increase the limited allograft allocation of highly sensitized patients—predefined by the
standard SAB–pan-IgG assay but restratified as non–C1q-binding DSAs by the SAB–C1q
assay—thereby shortening their waiting time.
Characterization of complement-activating anti-HLA DSAs may also have therapeutic signif-
icance, providing opportunities for the prevention and/or treatment of ABMR given the avail-
ability of specific drugs targeting complement or inhibiting complement-dependent cytotoxicity
[80–82]. The present study provides an important step toward a pathogenesis-based approach
for preventing and/or treating ABMR. Compared with the current approach to treatment,
which only considers the presence of circulating anti-HLA DSAs, a risk-stratified approach
on the basis of the complement-activating capacity of anti-HLA DSAs might significantly
improve the response rate to complement-inhibitor drugs. The validity of this approach has
recently been suggested in a clinical trial [83] in addition to post hoc analyses of 2 clinical trials
(NCT01567085 and NCT01399593) including kidney transplant recipients with preformed anti-
HLA DSAs receiving C5 inhibitor (eculizumab) for rejection prophylaxis, showing that the
effect of eculizumab on allograft function depends on the complement-activating capacity of
anti-HLA DSAs [84]. Further studies are needed for defining whether complement-activating
anti-HLA DSAs have the potential to inform therapeutic decision-making for timely interven-
tion and to streamline the use of expensive complement inhibitors in kidney transplantation.
We recognize the following limitations. We first acknowledge the higher proportion of kid-
ney recipients compared to heart, liver, and lung transplant recipients. We also acknowledge
that fewer studies regarding allograft rejection are included, which is partly due to the lack of
histological phenotyping provided by the allograft biopsy in certain studies. Further studies are
required to quantify the magnitude of the effect of complement-activating anti-HLA antibod-
ies on the risk of allograft rejection and the efficacy of ABMR therapies. Third, the timing of
anti-HLA detection is also a limitation, and because of the number of studies in the different
groups of DSA detection, a comparison between groups was not reliable. Fourth, no data were
available from Australian or South American transplant populations or from intestines or pan-
creas transplantation, limiting the extrapolation of our results to these patient populations.
Finally, almost all of the included studies were observational and retrospective. Confounding
factors from unknown origin may explain part of the residual heterogeneity observed.
In conclusion, circulating complement-activating anti-HLA DSAs represent a significant
determinant of long-term allograft survival and solid organ transplant rejection and may be
considered a potential valuable prognostic biomarker for improving the risk stratification for
allograft loss.
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Studies are listed by the date of publication. The black diamond-shaped boxes represent the
HR for each individual study. The grey boxes around the black diamond represent the weight
of the study, and lines represent the 95% CI for individual studies. The blue diamond at the
end represents the overall HR. CI, confidence interval; DSA, donor-specific antibody; HLA,
human leukocyte antigen; HR, hazard ratio.
(TIFF)
S3 Fig. Association between complement-activating anti-HLA DSAs and the risk of rejec-
tion. Studies comparing complement-activating anti-HLA DSAs with non–complement-acti-
vating anti-HLA DSAs. Studies are listed by date of publication. The black diamond-shaped
boxes represent the HR for each individual study. The grey boxes around the black diamond
represent the weight of the study, and lines represent the 95% CI for individual studies. The
blue diamond at the end represents the overall HR. CI, confidence interval; DSA, donor-spe-
cific antibody; HLA, human leukocyte antigen; HR, hazard ratio.
(TIFF)
Complement-activating anti-HLA antibodies and solid organ transplant survival: A meta-analysis
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002572 May 25, 2018 18 / 25
S4 Fig. Association of circulating complement-activating anti-HLA DSAs with the risk of
allograft loss including only high–methodological quality studies. Studies are listed by date
of publication. The black diamond-shaped boxes represent the HR for each individual study.
The grey boxes around the black diamond represent the weight of the study, and lines repre-
sent the 95% CI for individual studies. The blue diamond at the end represents the overall
HR. The number of patients in the overall population does not correspond to the sum of the
different groups for the studies of Kaneku et al. (2012) (3 patients) and Sicard et al. (2015) (4
patients) either because the data for these patients were missing or because they were not
involved in the analysis. CI, confidence interval; DSA, donor-specific antibody; HLA, human
leukocyte antigen; HR, hazard ratio.
(TIFF)
S5 Fig. Association of circulating complement-activating anti-HLA DSAs with the risk of
allograft loss stratified by the type of transplanted organ. Studies are listed by date of publi-
cation. The black diamond-shaped boxes represent the HR for each individual study. The grey
boxes around the black diamond represent the weight of the study, and lines represent the
95% CI for individual studies. The blue diamond at the end represents the overall HR. Number
of patients in the overall population does not correspond to the sum of the different groups for
the studies of Kaneku et al. (2012) (3 patients), Sicard et al. (2015) (4 patients), and Moktefi
et al. (2017) (3 patients) either because the data for these patients were missing or because they
were not involved in the analysis. CI, confidence interval; DSA, donor-specific antibody; HLA,
human leukocyte antigen; HR, hazard ratio.
(TIFF)
S6 Fig. Association of circulating complement-activating anti-HLA DSAs with the risk of
allograft loss stratified by the timing of anti-HLA DSA detection. Studies are listed by date
of publication. The black diamond-shaped boxes represent the HR for each individual study.
The grey boxes around the black diamond represent the weight of the study, and lines repre-
sent the 95% CI for individual studies. The blue diamond at the end represents the overall HR.
Number of patients in the overall population does not correspond to the sum of the different
groups for the studies of Kaneku et al. (2012) (3 patients), Sicard et al. (2015) (4 patients), and
Moktefi et al. (2017) (3 patients) either because the data for these patients were missing or
because they were not involved in the analysis. CI, confidence interval; DSA, donor-specific
antibodies; HLA, human leukocyte antigen; HR, hazard ratio.
(TIFF)
S7 Fig. Association of circulating complement-activating anti-HLA DSAs with the risk of
allograft loss according to the type of test used to determine complement-activating anti-
body capacity, either complement-binding antibody or IgG3 subclass. Studies are listed by
date of publication. The black diamond-shaped boxes represent the HR for each individual
study. The grey boxes around the black diamond represent the weight of the study, and lines
represent the 95% CI for individual studies. The blue diamond at the end represents the overall
HR. The number of patients in the overall population does not correspond to the sum of the
different groups for the studies of Kaneku et al. (2012) (3 patients), Sicard et al. (2015) (4
patients), and Moktefi et al. (2017) (3 patients) either because the data for these patients were
missing or because they were not involved in the analysis. CI, confidence interval; DSA,
donor-specific antibody; HLA, human leukocyte antigen; HR, hazard ratio.
(TIFF)
S8 Fig. Association of circulating complement-activating anti-HLA DSAs with the risk of
allograft loss after exclusion of the 3 largest studies [16,48,49]. Studies are listed by the date
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of publication. The black diamond-shaped boxes represent the HR for each individual study.
The grey boxes around the black diamond represent the weight of the study, and lines repre-
sent the 95% CI for individual studies. The blue diamond at the end represents the overall HR.
The number of patients in the overall population does not correspond to the sum of the differ-
ent groups for the studies of Kaneku et al. (2012) (3 patients), Sicard et al. (2015) (4 patients),
and Moktefi et al. (2017) (3 patients) either because the data for these patients were missing or
because they were not involved in the analysis. CI, confidence interval; DSA, donor-specific
antibody; HLA, human leukocyte antigen; HR, hazard ratio.
(TIFF)
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